In:
Oncology, S. Karger AG, Vol. 100, No. 3 ( 2022), p. 148-154
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Radiation-associated sarcoma (RAS) is one of the most life-threatening complications associated with the treatment of malignant neoplasms. Because all RAS patients have a history of radiotherapy, there have been no effective treatment options when RAS is not completely resected. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We retrospectively reviewed 20 RAS patients, including 4 unresectable cases treated by carbon ion radiotherapy (CIRT). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The primary diseases targeted by radiotherapy included malignant lymphoma ( 〈 i 〉 n 〈 /i 〉 = 4), cervical cancer ( 〈 i 〉 n 〈 /i 〉 = 3), pharyngeal cancer ( 〈 i 〉 n 〈 /i 〉 = 3), breast cancer ( 〈 i 〉 n 〈 /i 〉 = 2), lung cancer ( 〈 i 〉 n 〈 /i 〉 = 1), rectal cancer ( 〈 i 〉 n 〈 /i 〉 = 1), maxillary cancer ( 〈 i 〉 n 〈 /i 〉 = 1), synovial sarcoma ( 〈 i 〉 n 〈 /i 〉 = 1), and benign neoplasms ( 〈 i 〉 n 〈 /i 〉 = 4). The histological diagnoses of RAS included osteosarcoma ( 〈 i 〉 n 〈 /i 〉 = 8), leiomyosarcoma ( 〈 i 〉 n 〈 /i 〉 = 3), undifferentiated pleomorphic sarcoma ( 〈 i 〉 n 〈 /i 〉 = 3), rhabdomyosarcoma ( 〈 i 〉 n 〈 /i 〉 = 1), angiosarcoma ( 〈 i 〉 n 〈 /i 〉 = 1), malignant peripheral nerve sheath tumor ( 〈 i 〉 n 〈 /i 〉 = 1), spindle cell sarcoma NOS ( 〈 i 〉 n 〈 /i 〉 = 1), and sarcoma not further specified ( 〈 i 〉 n 〈 /i 〉 = 2). The median survival time from the diagnosis of RAS was 26 months. Eleven patients underwent surgery. Five of these patients achieved a continuous disease free (CDF) status or showed no evidence disease. Four patients underwent CIRT. One of these patients with leiomyosarcoma achieved a CDF status, and the other patient with osteosarcoma achieved a partial response. On the other hand, 2 patients experienced grade 3 toxicities that required surgical treatment. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 RAS originates from various types of diseases that are treated by radiotherapy and shows diverse pathological features. Complete resection achieves a good prognosis. CIRT can be an effective and feasible option for unresectable RAS.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink